Related Experiment Video
Updated: Jun 10, 2026

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
Published on: December 18, 2012
Prospects of a novel vaccination strategy for human gamma-herpesviruses
Ting-Ting Wu1, Marcia A Blackman, Ren Sun
1Department of Molecular and Medical Pharmacology, School of Medicine, University of California at Los Angeles, CA 90095, USA. twu@mednet.ucla.edu
Abstract:
Due to the oncogenic potential associated with persistent infection of human gamma-herpesviruses, including Epstein-Barr virus (EBV or HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8), vaccine development has focused on subunit vaccines. However, the results using an animal model of mouse infection with a related rodent virus, murine gamma-herpesvirus 68 (MHV-68, γHV-68, or MuHV-4), have shown that the only effective vaccination strategy is based on live attenuated viruses, including viruses engineered to be incapable of establishing persistence. Vaccination with a virus lacking persistence would eliminate many potential complications. Progress in understanding persistent infections of EBV and KSHV raises the possibility of engineering a live attenuated virus without persistence. Therefore, we should keep the option open for developing a live EBV or KSHV vaccine.
Related Concept Videos
Genital Herpes
Herpes
Human Virome
Smallpox
Antiviral Nucleoside Inhibitors
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

